Get the Foundayo Pill for Weight Loss – Online Prescription
Foundayo™ Pill for Weight Loss
Get Eli Lilly's Foundayo pill prescribed online through Walgreens Weight Management. Check your eligibility today. $49 per visit* + Foundayo pills start at $149/month for self-pay patients with a manufacturer’s savings card**.

Foundayo medication overview
- What is Foundayo medication?
Foundayo™ medication is the brand name for orforglipron , an FDA-approved oral GLP-1 medicine prescribed primarily for weight loss. Foundayo medication is a once daily tablet to help adults with obesity or those who are overweight with a weight-related health condition lose weight and keep it off when combined with diet and exercise. Foundayo medication belongs to a group of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists, alongside other weight-loss medications like Wegovy® ( semaglutide ) and Zepbound® ( tirzepatide ) medication. Click here for Additional Safety Information and Side Effects.
- How does Foundayo medication work?
Foundayo (orforglipron) medication works by mimicking the naturally occurring hormone GLP-1, which regulates blood sugar, appetite, and metabolism. It slows down the rate at which the stomach empties to make you feel fuller longer, and signals the brain to reduce appetite, which can lead to weight loss when combined with diet and exercise.
Foundayo (orforglipron) medication is different from other GLP-1 medications due to its small molecule structure compared to the large peptide molecules in other GLP-1 medications, such as semaglutide ( Wegovy ) or tirzepatide ( Zepbound ). A smaller molecular size may improve how your body absorbs the medication.
- Who can take Foundayo medication?
Foundayo medication is FDA-approved for weight reduction and long-term weight maintenance in adults who are obese or overweight with a weight-related health condition. Adults aged 18 years and older may be eligible for a GLP-1 medication through a Walgreens Weight Management visit – typically those with a Body Mass Index, or BMI, of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as hypertension, high cholesterol, liver disease, sleep apnea, or PCOS. Please note, prescription is based on medical evaluation and is not guaranteed.
Before taking Foundayo medication, make sure to discuss with your provider if you are pregnant, plan to be pregnant or are breastfeeding to discuss the risk versus benefit of the medication. GLP-1 medications are typically not recommended during pregnancy or breastfeeding due to the limited data on its safety in these cases. Foundayo cannot be used in patients with a personal or family history of MEN 2 (Multiple Endocrine Neoplasia Syndrome type 2) or medullary thyroid cancer (MTC).
For Medicare patients interested in Foundayo through the Medicare GLP-1 Bridge program, additional eligibility requirements may apply. Learn more and see if it may be right for you, here .
- Is Foundayo medication effective for weight loss?
The amount of weight someone loses when taking Foundayo medication can vary based on the medication dose, how consistently they take it, and their personal health conditions.
Research from clinical trials shows that Foundayo medication is effective for weight loss. Studies show that patients who are obese or overweight using Foundayo medication lose an average of 27.3 pounds (12.4%) when taking the highest dose alongside healthy diet and exercise. Individual results may vary.
- What is the difference between Foundayo medication and other drugs like Wegovy and Zepbound medication?
There are a few similarities and differences between Foundayo medication and other FDA-approved GLP-1 medications such as Wegovy and Zepbound medication. Click here for Additional Safety Information and Side Effects.
- Use/Eligibility:
- Foundayo (pills), Wegovy (pills and injectables), and Zepbound (injections) are all FDA-approved for weight reduction and long-term weight maintenance. Both Foundayo (orforglipron) and Zepbound (tirzepatide) medication are manufactured by Eli Lilly, while Wegovy (semaglutide) is manufactured by Novo Nordisk.
- Wegovy and Zepbound medication are also approved for other indications beyond weight loss.
- Wegovy is approved to lower the risk of major adverse cardiovascular events (MACE). Injectable Wegovy is also approved for the treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH).
- Zepbound medication is approved to treat moderate to severe obstructive sleep apnea in adults with obesity.
- Foundayo pills, Wegovy pills, and Zepbound injections are approved for adults 18 and older. While, the Wegovy injectable is approved for adults and pediatric patients aged 12 and older.
- Ingredients and Available Strengths:
- Foundayo pills contain orforglipron and are available in six strengths– 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg per tablet.
- The Wegovy pill and injection both contain semaglutide.
- Wegovy pills are available in four strengths–1.5 mg, 4 mg, 9 mg and 25 mg per tablet.
- Wegovy injections are available as single-dose pens in six strengths– 0.25 mg, 0.5 mg, 1 mg per 0.5ml and 1.7 mg, 2.4 mg and 7.2 mg per 0.75 mL.
- Zepbound injections contain tirzepatide and are available as multi-dose KwikPens, single-dose pens, or single-dose vials.
- Single-patient use KwikPens are available in six strengths that deliver 4 doses per KwikPen–2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg per 0.6 mL.
- Single-dose pens and vials are available in six strengths– 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL.
- Dosing and Administration:
- The Foundayo pill and the Wegovy pill are both taken by mouth once daily.
- The Foundayo pill should be taken around the same time of the day with or without food. Avoid breaking, crushing, or chewing the pill.
- The Wegovy pill should be taken first thing in the morning on an empty stomach with no more than 4 oz of water. Wait at least 30 minutes before eating, drinking anything else, or taking other medications and avoid splitting, crushing, chewing, or dissolving the pill.
- The injectable versions of GLP-1 medications, such as Wegovy and Zepbound, are more flexible as they are injected under the skin in the abdomen, thigh, or upper arm once weekly, on the same day, with or without food or water.
- Schedule: Patients on Foundayo pills or any other oral or injectable GLP-1 will be instructed to gradually increase their dose after 30 days (or 28 days) based on response and tolerance to help minimize side effects and achieve weight loss.
- The Foundayo pill and the Wegovy pill are both taken by mouth once daily.
- Use/Eligibility:
- What are the side effects of Foundayo?
Side effects of Foundayo medication are similar to those of Wegovy, Zepbound, and other GLP-1 medications. The side effects of Foundayo medication are generally mild to moderate in severity and the most commonly reported side effects include digestive issues such as nausea, vomiting, diarrhea, constipation, indigestion, stomach (abdominal) pain or swelling, gas, burping or reflux, as well as headache, fatigue, and hair loss. Speak with your provider for any questions or concerns about side effects you may be experiencing.
Other less common but serious side effects of Foundayo medication can also occur (for more details regarding side effects, see Additional Safety Information and Side Effects of GLP-1s topic below). GLP-1 medications carry an FDA black box warning about a potential risk for thyroid C-cell tumors and should be avoided in people with a history of personal or family history of medullary thyroid cancer. Notify your healthcare provider if you experience any of the following:- symptoms of thyroid problems such as a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath
- symptoms of pancreas or stomach problems such as severe pain in the stomach area that will not go away
- diarrhea, nausea or vomiting that does not go away
- symptoms of low blood sugar including sweating, shakiness, blurred vision, slurred speech, weakness, anxiety, hunger, headache, or confusion
- changes in vision
- symptoms of gallbladder problems including pain in your upper stomach, fever, yellowing of skin or eyes and clay-colored stool
You should stop taking Foundayo and get medical help if you experience symptoms of a serious allergic reaction including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy or rapid heartbeat.
There is an increased risk of food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Notify your providers that you are taking Foundayo or any GLP-1 before you are scheduled to have surgery or other procedures.
- Additional Safety Information and Side Effects of GLP-1s
Semaglutide (Wegovy), tirzepatide (Zepbound), orforglipron (Foundayo)
- Black Box Warning: (Wegovy, Zepbound, and Foundayo)
- Risk of thyroid C-cell tumors: Thyroid C-cell tumors have occurred in rodents. The risk in humans is undetermined.
- Contraindications: (Wegovy, Zepbound, and Foundayo)
- Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known serious hypersensitivity reactions to any of the ingredients in the product.
- Warnings and Precautions: (applies to Wegovy, Zepbound, and Foundayo unless indicated)
- Thyroid C-cell tumors have occurred in animal studies; human relevance of this finding has not been determined. Report symptoms of thyroid tumors (e.g., a lump in the neck, hoarseness, dysphagia, or dyspnea) to your healthcare provider.
- Inflammation of the pancreas (pancreatitis): contact your healthcare provider immediately if you have severe pain in your abdomen that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.
- Acute gallbladder disease or problems including gallstones have occurred. Call your healthcare provider if you have any of the following symptoms of gallbladder disease or complications: pain in your upper stomach (abdomen), yellowing of skin or eyes (jaundice), fever, or clay-colored stool.
- Hypoglycemia (low blood sugar) risk is increased when using a GLP-1 agonist, especially if also taking medications such as insulin or sulfonylureas. Symptoms of low blood sugar may include dizziness or light-headedness, sweating, shakiness, blurred vision, slurred speech, weakness, anxiety, hunger, headache, irritability or mood changes, confusion or drowsiness, fast heartbeat, or feeling jittery.
- Acute kidney injury: Diarrhea, nausea, and vomiting may lead to dehydration which may cause kidney problems such as acute kidney injury and, in rare cases, requiring hemodialysis. It is important that you drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away. (Zepbound and Foundayo only)
- Gastrointestinal adverse reactions, sometimes severe, have been reported. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
- Hypersensitivity reactions: stop using the GLP-1 agonist and get medical help right away if you have any symptoms of a serious allergic reaction including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, fainting or feeling dizzy.
- Increased heart rate may occur, even when at rest. Consider monitoring and tell your healthcare provider if you feel your heart racing or pounding in your chest, lasting for several minutes. (Wegovy only)
- Severe gastroparesis or delayed stomach emptying: These medications slow gastric emptying and are not recommended in patients with severe gastroparesis. Inform your healthcare provider if you have severe stomach emptying problems or persistent symptoms such as severe nausea, vomiting, abdominal pain, or inability to tolerate food.
- Increased risk of pulmonary aspiration (food getting into your lungs) during surgery or other procedures that use anesthesia or deep sedation due to delayed gastric emptying. Tell all your healthcare providers that you are taking this GLP-1 agonist before you are scheduled to have surgery or other procedures.
- Changes in vision: Tell your healthcare provider if you have changes in vision. Diabetic retinopathy can worsen in patients with type 2 diabetes.
- Pregnancy and breastfeeding: Speak with your provider if you are or plan to be pregnant or breastfeeding, as these GLP-1 agonists should generally not be used during pregnancy or breastfeeding or only be used during pregnancy or breastfeeding if the potential benefit outweighs potential risk to the fetus or breastfed infant.
- Do not share your medication pen or needles with anyone else. You may give an infection to them or get an infection from them.
- Common Side Effects
- Wegovy: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, belching, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and changes in touch sensation, and hair loss.
- Zepbound: nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, decreased appetite, dizziness, injection site reactions, fatigue, hypersensitivity reactions, belching, hair loss, gastroesophageal reflux disease (GERD).
- Foundayo: nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, reflux, gas, hair loss.
- Drug or Food Interactions (applies to Wegovy, Zepbound, and Foundayo unless indicated)
- Delayed gastric emptying may impact absorption of other oral medications taken along with GLP-1 agonists. Additional monitoring may be required for patients who take medications that have a narrow therapeutic index or require clinical monitoring.
- Use of GLP-1 medications may reduce the efficacy of oral hormonal contraceptives (birth control). If you are using oral hormonal contraceptives, add a non-oral contraceptive method or a barrier method of contraception for 4 weeks after starting Zepbound (30 days for Foundayo) and for 4 weeks after each Zepbound dose increase (30 days after each Foundayo dose increase). (Zepbound and Foundayo only)
- Medications metabolized primarily through the CYP3A4 enzyme pathway in the liver can affect medication levels. Check with your doctor if any adjustments are required. (Foundayo only)
- Increased risk of severe hypoglycemia may occur in patients who are also using insulin or a sulfonylurea. Dose reduction of insulin or sulfonylurea may be required.
- Be sure to tell your healthcare provider about all the medications you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. GLP-1 agonist medications can change how some medicines work, and other medicines may affect how GLP-1 medications work too.
- Simvastatin use with Foundayo: Do not exceed simvastatin 20 mg once daily when used concomitantly with Foundayo. (Foundayo only)
- Black Box Warning: (Wegovy, Zepbound, and Foundayo)
- How to get prescribed Foundayo medication online?
Walgreens Weight Management makes it simple and convenient to get weight management support online. After reviewing your medical history, our licensed providers will determine if treatment is clinically appropriate. If so, they will create a personalized treatment plan and prescribe a weight loss medication that you can pick up at your local Walgreens or a pharmacy of your choice. Talk to a Walgreens Weight Management provider today to see if Foundayo is right for you.
- How much does Foundayo medication cost?
Eligible patients with commercial insurance may pay as little as $25/month for Foundayo with a manufacturer’s savings card.† Eligible self-pay patients may pay as little as $149/month for the two lowest doses with a manufacturer’s savings card, subsequent doses range from $199-$299/month.† Restrictions and exclusions apply, see applicable manufacturer offer terms below. Please note, the cost of the Walgreens Weight Management visit is separate from the cost of the medication.
Medicare patients eligible for the Medicare GLP-1 Bridge program can pay a $50/month copay§ on select FDA-approved GLP-1s including Foundayo. Learn more here.
Frequently Asked Questions
Medication Specifics
- Can I switch from other GLP-1s (Wegovy, Zepbound) to Foundayo medication?
Yes, it is possible for patients to switch to Foundayo from another GLP-1 medication like Wegovy or Zepbound. Studies found that people using either Wegovy or Zepbound medication were able to maintain the weight they lost after switching to Foundayo medication. However, this change should only happen with your healthcare provider's guidance and will require an updated prescription prior to switching. Click here for Additional Safety Information and Side Effects.
The dose will depend on the current or most recently used dose and can be determined by the provider. The appropriate instructions and timing requirements should be followed when switching to Foundayo medication. If switching from the injection to the Foundayo pill, start the pill one week after the last injection dose. If switching from the Wegovy pill to the Foundayo pill, the Foundayo pill can be started the day after stopping the Wegovy pill.
- Is Foundayo medication FDA-approved?
Yes, Foundayo medication is approved by the FDA for certain conditions including:
Weight reduction and long term weight maintenance in adults (18 years and older) who have obesity, and in adults who are overweight with at least one weight-related health condition such as high blood pressure or high cholesterol. It is meant to be used along with a reduced-calorie diet and increased physical activity.
- How do you take Foundayo medication?
The Foundayo pill should be taken once daily with or without food. Swallow the tablet whole. Do not break, crush or chew the tablet. It is recommended to start at 0.8 mg daily and increase the dose every 30 days as tolerated and instructed by your healthcare provider to a maximum maintenance dose of 17.2 mg. Many people begin to see weight loss within the first few weeks of treatment, with ongoing, dose-dependent weight loss that continues over time when taking Foundayo medication as prescribed.
If a dose is missed, take the next dose as soon as possible but do not double up the next dose. If 7 or more doses are missed, it is recommended to restart with a lower dose to help reduce side effects. You can talk to your prescriber for guidance.
- How long do I need to be on it?
Patients typically begin with a low dose of a GLP-1 agonist medication, such as Foundayo medication, which is gradually increased for effective weight loss. The initial months of treatment allow you to adjust to the medication and lifestyle changes while starting to lose weight. Your dosage may be modified over time depending on your weight loss and any side effects you may experience.
Studies show that patients who are obese or overweight using Foundayo medication lose an average of 27.3 pounds (12.4%) when taking the highest dose alongside healthy diet and exercise. Weight loss can be maintained as long as the patient follows healthy lifestyle habits and continues taking the medication as prescribed.
- How often do I need to check in with a provider?
Initially, most patients check in monthly so their provider can adjust their medication dosage for the best results. Once weight loss stabilizes, check-ins typically become less frequent – about every 3 to 6 months, depending on your provider's recommendation. If you need additional support to discuss side effects, switching medications, dosing, or other questions or concerns, you can request an on-demand “Weight Management - Additional Care” video visit with a Walgreens Weight Management provider 7 days a week (7 a.m. to 11 p.m. CST).
Prescription Details
- Can I get a Foundayo prescription online?
Yes! To begin the process, you can start a virtual visit through our Walgreens Weight Management service. A provider will review your medical history and current medications to confirm you are eligible for weight management treatment. If it's clinically appropriate and safe, your provider will create a personalized treatment plan and may prescribe Foundayo medication.
- Does insurance cover Foundayo medication?
You may be able to use insurance to help pay for GLP-1 medications prescribed through Walgreens Weight Management, including Foundayo. Walgreens Weight Management now offers prior authorization support on GLP-1 medication for eligible patients with commercial insurance. Please note, medication cost is separate from the visit fee and insurance is not currently accepted for Walgreens Weight Management visits at this time. For more details about pricing, please see “How much does Foundayo medication cost?” question above.
Medicare patients, click here to learn how the Medicare GLP-1 Bridge program can help cover a portion of your GLP-1 medication costs.
- Can Walgreens prescribe any other medications for weight loss?
Yes! In addition to Foundayo (orforglipron) medication, Walgreens Weight Management supports other GLP-1 agonist medications for weight loss such as tirzepatide ( Zepbound - injectable KwikPens and vials) and semaglutide ( Wegovy - oral pills & injectable pens). A doctor or nurse practitioner will evaluate which GLP-1 agonist is right for you by considering your unique health factors, including your BMI and medical history, and will recommend what is most appropriate for your needs.
References
Last updated: October 14, 2026.
- Foundayo Package Insert. 2026. Eli Lilly and Company. foundayo-uspi.pdf
- Eli Lilly and Company. FDA approves Lilly’s Foundayo. FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions | Eli Lilly and Company, Accessed April 2026.
- Eli Lilly and Company. Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial | Eli Lilly and Company, Accessed March 2026.
- Wegovy. Package insert. Novo Nordisk; 2026. https://www.novo-pi.com/wegovy.pdf
- Zepbound. Package insert. Eli Lilly and Company. 2026. https://uspl.lilly.com/zepbound/zepbound.html#
- The New England Journal of Medicine. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | New England Journal of Medicine, Accessed March 2026.
- Eli Lilly and Company. What to Know About Orforglipron Oral GLP-1 | Eli Lilly and Company
- Wharton S, Blevins T, Connery L, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial, The Lancet. Accessed March 2026.
- Eli Lilly and Company. Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity | Eli Lilly and Company. Accessed March 2026.
- Eli Lilly and Company. Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial | Eli Lilly and Company. Accessed March 2026.
- Drugs.com. What is orforglipron? Accessed March 2026.
Disclaimers
*Medication not included. Rx based on medical evaluation.
**Starting $149/month self-pay pricing available on select doses and medications, pricing may be available for a limited time and is subject to change. Visit price not included. Restrictions apply. Prices are medication-, presentation-, and dose-specific; starting-dose prices are not maintenance-dose prices.
***Eligible commercially insured patients with GLP-1 coverage may pay as little as $25/month for the medication with a manufacturer’s savings card. Eligibility, prior authorization and coverage rules apply. Contact your plan for details. Pricing and availability subject to change. Visit price not included. Prices are medication-, presentation-, and dose-specific; out-of-pocket cost may vary over time based on factors such as health plan benefits, deductible status, and eligibility for manufacturer savings programs.
§ $50/month copayment covers GLP-1 medication for weight loss through Medicare GLP-1 Bridge program only; healthcare services (including visit costs) are not included. Eligibility, prior authorization and coverage rules apply. Contact your plan or healthcare provider for details.
Please note that the pricing listed is not Walgreens’s usual and customary price.
Walgreens Weight Management is currently available in all U.S. states except AL. For Medicare Bridge patients, Walgreens Weight Management is available in all U.S. states except AL, DC, DE, KS, LA, MS, NM, RI, and WV.
Based on national averages. Actual wait times may vary.
The Medicare GLP-1 Bridge program is a separate program offered by CMS, supported by Walgreens Pharmacy and other pharmacies to help Medicare patients with an existing GLP-1 prescription pay for their GLP-1s. An existing prescription alone may not establish eligibility.
Prescription based on medical evaluation and not guaranteed. Providers include doctors or nurse practitioners. Other restrictions may apply. For side effects, see “Additional Safety Information and Side Effects for GLP-1s” content above.
Walgreens-affiliated medical practices are independently owned and operated by licensed physicians who provide services using the Walgreens virtual care program telehealth platform. For more information about the relationship between Walgreens and the medical practices click here.
Walgreens Health Medical Group California P.C. is a California professional medical corporation utilizing the fictitious name "Walgreens Health Medical Group California P.C." pursuant to Cal. Bus. & Prof. Code § 2415. To view the Fictitious Name Permit click here.
This content references third-party trademarks that are the property of their respective owners. Such references are made for informational purposes only and are not sponsored, authorized, or endorsed by, or otherwise affiliated with, the respective trademark owners.
Please note that a GLP-1 medication may not be appropriate in all patients.
† Lilly’s Foundayo Savings Card Program: For commercially insured patients with Foundayo coverage: Through December 31, 2026, Lilly is offering Foundayo for as little as $25 for 1-month, 2-month, or 3-month prescription fills to commercially insured patients with Foundayo coverage. Subject to a maximum savings of $100 per month. A 1-month supply is defined as 30 days, a 2-month supply is defined as 60 days, and a 3-month supply is defined as 90 days. Participation in the Program requires a valid patient HIPAA authorization. This offer is not valid for patients enrolled in any federal, state, or government funded healthcare program (including Medicare, Medicaid, and TRICARE). Lilly reserves the right to terminate, rescind, revoke, or amend the savings card eligibility criteria and/or term conditions at any time without notice and for any reason. See full terms at https://foundayo.lilly.com/coverage-savings#commercial-terms.
For patients planning to self-pay: Through December 31, 2026, Lilly is offering eligible self-pay patients both 0.8 mg and 2.5 mg doses of Foundayo medication for $149 per month, 5.5 mg doses for $199 per month, and 9 mg, 14.5 mg, and 17.2 mg doses for $299 per month. Each fill equals a 30-supply, which is equivalent to one month of medication. To continue to be eligible for this offer, patients must complete their refill purchase of Foundayo within 45 days of the delivery/received date of your previous Foundayo prescription fill. Card may be used for a maximum of up to 10 prescription fills per calendar year. This offer is for self-paying patients only and operates outside of any third-party insurance. Patients agree not to seek or accept reimbursement for any out-of-pocket costs from any third-party. Lilly reserves the right to terminate, rescind, revoke, or amend the savings card eligibility criteria and/or term conditions at any time without notice and for any reasons. See full terms at https://foundayo.lilly.com/coverage-savings#self-pay-terms.


